FBG (mmol/L) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Kidney function markers · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Death: unknown time frame · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes death (any cause) Time frame: 1 to 5 years compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Transplant or graft survival · pre‐existing and new‐onset diabetes in kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Variation in the decrease in 24‐hour ambulatory hourly SBP (at 3 to 12 weeks) · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
no estimate extracted
121 participants
Very low
Variation in the decrease in 24‐hour ambulatory hourly DBP (at 3 to 12 weeks) · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
no estimate extracted
121 participants
Very low
Variation in the decrease in 24‐hour ambulatory hourly HR (at 3 to 12 weeks) · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
no estimate extracted
71 participants
Very low
Intervention not reported
Cerivastatin dose · participants with normal or abnormal lipid profiles
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
0.05 mg/d · participants with normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
0.1 mg/d · participants with normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
0.2 mg/d · participants with normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
0.3 mg/d · participants with normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
0.4 mg/d · participants with normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
0.8 mg/d · participants with normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
CI: confidence interval · participants with normal or abnormal lipid profiles
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
aMean baseline values. · participants with normal or abnormal lipid profiles
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Cerivastatin dose · participants with normal or abnormal lipid profiles
The review found no eligible studies for this question.
1 finding from 1 review